Project Grant R44DK141418
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$349K
Awardee
Regennova, Inc. (K9VQL9BKC1A9)
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $1,472,604 to support research on cyst induction and growth in autosomal dominant polycystic kidney disease (ADPKD). The award was granted to the Children's Hospital Medical Center in Cincinnati, Ohio, and will fund a research project from August 2024 through May 2029. The key objectives are to investigate...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $223,918 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the University of Oklahoma Health Sciences Center. The purpose of this 20-month grant, awarded on September 28, 2024, is to study niche filling as a means to achieve long-term, kidney-specific depletion of resident macrophages in order to slow the progression of autosomal dominant polycystic...
This $675,480 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research to develop a novel therapeutic compound for treating chronic kidney disease (CKD). The awardee, Fibrotherapeutics Inc., is conducting preclinical studies to evaluate the efficacy, safety, and therapeutic index of a modified, water-soluble, orally-active peptide derived...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $135,582 Project Grant (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) to the University of Oklahoma Health Sciences Center to construct a single-cell atlas of mouse and human cells in autosomal dominant polycystic kidney disease (ADPKD). The project aims to understand how molecular and cellular pathways found in ADPKD patients correlate to mouse models, and to identify inter-...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $640,001 to Yale University to conduct research on the mechanisms and function of the protein Polycystin-1 (PC1) in the context of autosomal dominant polycystic kidney disease (ADPKD). The key objectives are to: 1) determine if a specific 200 amino acid fragment of PC1 can...
The University of Pittsburgh received a $198,750 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) to develop a rapid, quantitative platform using yeast to classify how approximately 70 identified mutations in the polycystin-1 (PC1) protein disrupt channel activity with PC2. This research aims to provide new reagents and assays to the scientific and PKD (polycystic kidney disease) community to study the molecular defects of PC1 mutants. The...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research, provides $587,212 to the University of Alabama at Birmingham (UAB) to conduct research on the role of the CDKN1A (P21) gene in polycystic kidney disease (PKD). The goal of the research is to determine how abnormal regulation of the P21 gene, which is involved in cell cycle control and tissue repair, contributes...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $1,145,486 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Makscientific LLC, a for-profit research and development company located in Burlington, MA. The grant supports the development of novel peripherally acting CB1 neutral antagonists for treating diabetic kidney disease (DKD). The project aims to design and synthesize improved analogs of...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) provides $647,486 to Inlighta Biosciences LLC, a woman-owned small business located in Marietta, Georgia. The award supports research aimed at developing calcium-sensing receptor (CaSR) targeted theragnostic agents and imaging agents for polycystic kidney disease (PKD) and other CaSR-associated...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $1,712,226 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Orphagen Pharmaceuticals, Inc. The grant supports the development of a novel, first-in-class class of small molecule antagonists that inhibit the gut migration of activated T cells, which is a promising therapeutic approach for treating inflammatory bowel disease (IBD). Preliminary data...